These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8534589)

  • 41. Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors.
    van Eyck CH; Bruining HA; Reubi JC; Bakker WH; Oei HY; Krenning EP; Lamberts SW
    World J Surg; 1993; 17(4):444-7. PubMed ID: 8395748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide.
    Nocaudie-Calzada M; Huglo D; Deveaux M; Carnaille B; Proye C; Marchandise X
    J Nucl Med; 1994 Jan; 35(1):57-62. PubMed ID: 8271061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma.
    Kopf D; Bockisch A; Steinert H; Hahn K; Beyer J; Neumann HP; Hensen J; Lehnert H
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):39-44. PubMed ID: 9059556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
    Brabander T; Teunissen J; Kwekkeboom D
    Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatostatin receptor imaging and therapy of pancreatic endocrine tumors.
    van Eijck CH; de Jong M; Breeman WA; Slooter GD; Marquet RL; Krenning EP
    Ann Oncol; 1999; 10 Suppl 4():177-81. PubMed ID: 10436816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medical treatment of benign insulinoma using octreotide LAR: a case report.
    Usukura M; Yoneda T; Oda N; Yamamoto Y; Takata H; Hasatani K; Takeda Y
    Endocr J; 2007 Feb; 54(1):95-101. PubMed ID: 17124362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders.
    Friess H; Büchler MW
    Digestion; 1996; 57 Suppl 1():97-102. PubMed ID: 8813484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreas.
    Lange JR; Steinberg SM; Doherty GM; Langstein HN; White DE; Shawker TH; Eastman RC; Jensen RT; Norton JA
    Surgery; 1992 Dec; 112(6):1033-7; discussion 1037-8. PubMed ID: 1455306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
    Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
    Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
    Degen L; Beglinger C
    Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
    Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
    J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
    Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
    Nauck C; Ivancević V; Emrich D; Creutzfeldt W
    Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term follow-up of two patients with metastatic neuroendocrine tumours treated with octreotide.
    van de Loosdrecht AA; van Bodegraven AA; Sepers JM; Sindram JW
    Neth J Med; 1998 Sep; 53(3):118-23. PubMed ID: 9803143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
    Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
    J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.
    Krassas GE; Dumas A; Pontikides N; Kaltsas T
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.